ASCO 2023: Focus on Breast Cancer
Patients with HR+/HER2- early-stage breast cancer classified as H2 were more likely to respond to chemotherapy.
Even with a recurrence score <11, patients who were staged higher had worse overall survival.
Some organizations recommend annual breast cancer screenings for women over 40, but what is the lifetime cost?
Rural residents had lower breast cancer-specific survival and a higher risk of relapse, though the reasoning is unclear.
Patients with the UGT1A1 *28/*28 genotype were more likely to experience toxicity leading to discontinuation of SG.
Multivariable analysis showed no factors associated with HER2 low compared to HER2- or HER2+ tumors.
Male breast cancer is rare, and little has been documented about prognosis, outcomes, and demographics.
Do breast satisfaction and sexual well-being play a role in choosing between lumpectomy or mastectomy?
The prognosis was worse for Black and young women with MBC, as seen in studies of women with early breast cancer.
HER2-low status was associated with better OS and longer time-to-distant recurrence in a single-institution study.
The proportion of patients receiving treatment and 2-year overall survival increased, and time-to-treatment decreased.
Although the demographics and treatment initiation differed, real-world clinical outcomes were similar to the ASCENT Trial.
Women with indolent metastatic breast cancer not undergoing cytotoxic chemotherapy are currently sought for the EMBody Trial.
Women younger than 40 diagnosed with in situ primary BC were 5 times more likely to develop second primary BC.
Women younger than 40 with a BMI over 30 were more likely to have triple-negative breast cancer.
The largest racial disparity was found in 2018. In addition, a quarter of eligible patients never initiated treatment.
Despite a 28-month OS benefit, public funding is lacking for those eligible for further lines of treatment.
Outcomes with the antibody-drug conjugate did not differ between levels of TACSTD2 mRNA expression.
This study’s overall 5-year breast cancer-specific survival was excellent, regardless of tumor size or chemotherapy status.
Sacituzumab govitecan outperformed treatment of physician’s choice in overall survival benefit at final clinical follow-up.
Advertisement
Advertisement
